These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 37387918)

  • 1. Retracted: High CHAF1A Expression Levels Are Positively-Correlated with PD-L1 Expression and Indicate Poor Prognosis in Gastric Cancer.
    And Alternative Medicine EC
    Evid Based Complement Alternat Med; 2023; 2023():9876457. PubMed ID: 37387918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High CHAF1A Expression Levels Are Positively-Correlated with PD-L1 Expression and Indicate Poor Prognosis in Gastric Cancer.
    Bao Z; Zhang Y; Yu P; Wang Y; Hu C; Xia Y; Yuan L; Xu Z; Cheng X
    Evid Based Complement Alternat Med; 2022; 2022():1323321. PubMed ID: 35911136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of CHAF1A is associated with poor prognosis, tumor immunosuppressive microenvironment and treatment resistance.
    Sun X; Ma Q; Cheng Y; Huang H; Qin J; Zhang M; Qu S
    Front Genet; 2023; 14():1108004. PubMed ID: 36968583
    [No Abstract]   [Full Text] [Related]  

  • 4. The Expression of PD-L1 and B7-H4 in Thymic Epithelial Tumor and Its Relationship With Tumor Immune-Infiltrating Cells.
    Yan X; Feng J; Hong B; Qian Y
    Front Oncol; 2021; 11():662010. PubMed ID: 34307135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CHAF1A interacts with TCF4 to promote gastric carcinogenesis via upregulation of c-MYC and CCND1 expression.
    Zheng L; Liang X; Li S; Li T; Shang W; Ma L; Jia X; Shao W; Sun P; Chen C; Jia J
    EBioMedicine; 2018 Dec; 38():69-78. PubMed ID: 30449701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retracted: Risk Analysis of Positive PD-L1 Expression and Clinicopathological Features and Survival Prognosis in Patients with Colorectal Cancer: Systematic Review and Meta-Analysis.
    Healthcare Engineering JO
    J Healthc Eng; 2023; 2023():9873196. PubMed ID: 37564813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-expression of CMTM6 and PD-L1: a novel prognostic indicator of gastric cancer.
    Zhang C; Zhao S; Wang X
    Cancer Cell Int; 2021 Jan; 21(1):78. PubMed ID: 33509216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Relationship between PD-L1 protein expression and gene amplification in gastric cancer tissues].
    Liu Y; Wang JF; Li XW; Bu P; Bai W; Li LM
    Zhonghua Bing Li Xue Za Zhi; 2018 Aug; 47(8):597-602. PubMed ID: 30107664
    [No Abstract]   [Full Text] [Related]  

  • 9. The prediction of survival of patients with gastric cancer with PD-L1 expression using contrast-enhanced ultrasonography.
    Wang LA; Wei X; Li Q; Chen L
    Tumour Biol; 2016 Jun; 37(6):7327-32. PubMed ID: 26671554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-1 and PD-L1 co-expression predicts favorable prognosis in gastric cancer.
    Wu Y; Cao D; Qu L; Cao X; Jia Z; Zhao T; Wang Q; Jiang J
    Oncotarget; 2017 Sep; 8(38):64066-64082. PubMed ID: 28969052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone chaperone CHAF1A impacts the outcome of fluoropyrimidines-based adjuvant therapy in gastric cancer by regulating the expression of thymidylate synthetase.
    Wang D; Li X; Shen B; Chen X; Shu Y
    Gene; 2019 Oct; 716():144034. PubMed ID: 31377317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low Expression of Programmed Death 1 (PD-1), PD-1 Ligand 1 (PD-L1), and Low CD8+ T Lymphocyte Infiltration Identify a Subgroup of Patients With Gastric and Esophageal Adenocarcinoma With Severe Prognosis.
    Däster S; Eppenberger-Castori S; Mele V; Schäfer HM; Schmid L; Weixler B; Soysal SD; Droeser RA; Spagnoli GC; Kettelhack C; Oertli D; Terracciano L; Tornillo L; von Holzen U
    Front Med (Lausanne); 2020; 7():144. PubMed ID: 32411711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retracted: Expression of PD-L1 and BRCA1 in Triple-Negative Breast Cancer Patients and Relationship with Clinicopathological Characteristics.
    And Alternative Medicine EC
    Evid Based Complement Alternat Med; 2023; 2023():9815452. PubMed ID: 37388050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retracted: Clinical Efficacy and Safety Analysis of PD-1/PD-L1 Inhibitor vs. Chemotherapy in the Treatment of Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    International BR
    Biomed Res Int; 2022; 2022():9808495. PubMed ID: 36597467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retracted: IFN-
    Intelligence And Neuroscience C
    Comput Intell Neurosci; 2023; 2023():9845607. PubMed ID: 38074393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retracted: Study on PD-L1 Expression in NSCLC Patients and Related Influencing Factors in the Real World.
    Methods In Medicine CAM
    Comput Math Methods Med; 2023; 2023():9808707. PubMed ID: 37475945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1 Expression and CD8
    Wang Y; Zhu C; Song W; Li J; Zhao G; Cao H
    J Immunol Res; 2018; 2018():4180517. PubMed ID: 30003113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retracted: Molecular Mechanism of Expression Changes of Immunological Indexes of PD-1/sPD-L1 after Radiotherapy in Nonsmall Cell Lung Cancer.
    International BR
    Biomed Res Int; 2024; 2024():9865398. PubMed ID: 38230195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retracted: Abnormal COX2 Protein Expression May Be Correlated with Poor Prognosis in Oral Cancer: A Meta-Analysis.
    International BR
    Biomed Res Int; 2021; 2021():3284807. PubMed ID: 33681352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retracted: Analysis of the Role and Mechanism of ZEB1 in Regulating Cervical Carcinoma Progression via Modulating PD-1/PD-L1 Checkpoint.
    Methods In Medicine CAM
    Comput Math Methods Med; 2023; 2023():9783548. PubMed ID: 37811258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.